Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Aarntzen, Erik Hjg ^a,b   Srinivas, Mangala ^a   Schreibelt, Gerty ^a   Heerschap, Arend ^b   Punt, Cornelius J A ^c   Figdor, Carl G ^a   Oyen, Wim J ^b   de Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

19F MRI; Dendritic cell; Imaging; Immunotherapy; Migration

Indexed keywords

DENDRITIC CELL VACCINE; FLUORINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMIQUIMOD; INDIUM 111; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNIZATION; CELL COUNT; CELL HOMING; CELL LABELING; CELL MIGRATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; IMMUNOSTIMULATION; ISOTOPE LABELING; LYMPH NODE; MELANOMA; METASTATIC MELANOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTIGRAPHY; T LYMPHOCYTE ACTIVATION;

EID: 84886945306     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24661     Document Type: Article

References (10)

1. Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, et al. Imaging of cellular therapies. Adv Drug Deliv Rev, 2010; 62:1080-93; PMID:20800081; http://dx.doi.org/10.1016/j. addr.2010.08.009.
2. Martin-Fontecha A, Sebastiani S, Höpken UE, Uguccioni M, Lipp M, Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med, 2003; 198:615-21; PMID:12925677; http://dx.doi.org/10.1084/jem.20030448.
3. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther, 2008; 8:865-74; PMID:18549318; http://dx.doi. org/10.1517/14712598.8.7.865.
4. Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res, 2013; 19:1525-33; PMID:23382117; http://dx.doi.org/10.1158/1078-0432.CCR-12-1879.
5. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res, 2009; 15:2531-40; PMID:19318472; http://dx.doi. org/10.1158/1078-0432.CCR-08-2729.
6. Bonetto F, Srinivas M, Weigelin B, Cruz LJ, Heerschap A, Friedl P, et al. A large-scale (19)F MRI-based cell migration assay to optimize cell therapy. NMR Biomed, 2012; 25:1095-103; PMID:22315137; http://dx.doi. org/10.1002/nbm.2774.
7. Srinivas M, Heerschap A, Ahrens ET, Figdor CG, de Vries IJ. (19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol, 2010; 28:363-70; PMID:20427096; http://dx.doi.org/10.1016/j. tibtech.2010.04.002.
8. Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, de Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials, 2010; 31:7070-7; PMID:20566214; http://dx.doi. org/10.1016/j.biomaterials.2010.05.069.
9. Celli S, Day M, Müller AJ, Molina-Paris C, Lythe G, Bousso P. How many dendritic cells are required to initiate a T-cell response?. Blood, 2012; 120:3945-8; PMID:22995897; http://dx.doi.org/10.1182/blood-2012-01-408260.
10. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration modulates the induction of dendritic cell vaccineinduced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res, 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432.CCR-11-1261